lung cancer | |||||
新闻 | |||||
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, ...
| |||||
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities Impact: Dietary zinc supplementation may help improve outcomes in lung cancers reliant on glutathione reductase ... cancer dependency, which was ...
| |||||
Candel Therapeutics Provides Corporate Update and FDA granted Orphan Drug Designation for CAN-2409 in borderline resectable PDAC in April 2024. CAN-2409 – Non-Small Cell Lung Cancer. At the 2024 ...
| |||||
查看更多结果 | 修改此快讯 |
您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
发送反馈 |
No comments:
Post a Comment